obesity-995x60.png
FEATURED ARTICLES
Helus Shares Experience Studying Adjunctive Psychedelic For Major Depressive Disorder
Helus Pharma CMO Amir Inamdar discusses the strategic rationale behind its Phase 3 trial for major depressive disorder, including its adjunctive-treatment approach, patient population selection, and endpoint strategy.
-
What Is Interactive Response Technology (IRT)?
Learn how protocol-driven IRT systems support supply management and randomization to help trial teams cut risk and costs.
-
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.
-
RWE Increasingly Supports Rare Disease Research As RCTs Alone Fall Short
Chiesi's Rachele Berria, MD, Ph.D., discusses how RWE is reshaping rare disease drug development strategies, from leveraging registries and patient-reported outcomes to navigating evolving regulatory expectations.